http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017202891-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ef3d397d8ae4a0defb3ad039d551c08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6cfe6310005f06724c9acafb7882113 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-00043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-00032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-523 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
filingDate | 2017-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95879fa5494c1035704abe63bb31018b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42541319306ad7d242b95ac1b12948b8 |
publicationDate | 2017-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2017202891-A1 |
titleOfInvention | Pegylated recombinant bacteriophage |
abstract | The present invention provides a recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides methods of treatment of mammalian subjects having a bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides pharmaceutically acceptable formulations of recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides a method of inducing an antibacterial immune response in a mammalian subject having bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides a recombinantly modified PEGylated bacteriophage that avoids neutralization by the Cas9 system. In one embodiment, the present invention further provides a recombinantly modified PEGylated bacteriophage expressing an anti-Cas9 protein. The present invention further provides a recombinantly modified PEGylated bacteriophage the genome of which has been modified to eliminate one or more protospacer adjacent motifs. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111278975-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021108442-A3 |
priorityDate | 2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 592.